Compare ADMA Biologics Inc (ADMA) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Cenovus Energy Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Cenovus Energy Inc trades at $26.41 (market cap $47.02B). The key difference: Cenovus Energy Inc is far larger — about 22.1× ADMA Biologics Inc's market cap, and Cenovus Energy Inc pays a 2.46% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CVE | |
|---|---|---|
Market Cap | $2.13B | $47.02B |
Sector | Health | Energy |
52-Week High | $20.38 | $31.80 |
52-Week Low | $7.60 | $13.96 |
Enterprise Value | $2.20B | $54.90B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Cenovus Energy (CVE) trades at $25.21, up 2.27% with a bearish technical signal. Recent earnings beats and an attractive P/E of 13.78 highlight fundamental strength, while cash flow trends show operational resilience despite negative net flows. The company maintains a solid balance sheet with a debt-to-asset ratio of 13.63% as of 2024.
CVE offers value with low valuation multiples and consistent profitability, but faces headwinds from volatile oil prices and regulatory challenges. Analyst consensus is mixed with 40.74% buy ratings, suggesting cautious optimism for long-term growth amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
